Clinical Trial Update: A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer [Phase 2]

View source ↗

Summary

Multicenter Phase II trial investigating neoadjuvant Camrelizumab in combination with chemotherapy for organ preservation in esophageal cancer; currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Esophageal Cancer | Phase 2 | Status: RECRUITING